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ligand ligand expression Receptor/expression function of Receptor on t cells Implications for Human disease
B7-1 (CD80) Inducible: APCs (slower  kinetics 
than B7-2), T cells
CD28
Constitutive: mouse (all T 
cells), human (95% of CD4+, 
50% of CD8+ T cells), plasma 
cells, NK cells
Stimulation of naive and previously activated T cells upon TCR 
ligation: ↑ proliferation (↓ p27Kip1, ↑ G1/S); ↑ cytokine production 
(↑ NFκB, ↑ IL2); ↑ survival (↑ Bcl-xL, ↑ survival of Tregs); ↑ 
glucose metabolism; provides T cell-dependent B cell help for 
class switching. 
Blockade of pathway to treat 
 autoimmune infl ammatory  diseases 
and for transplantation; active 
 engagement to expand anti-tumor T 
cells and Tregs
B7-2 (CD86) Constitutive at low levels; 
inducible: APCs, T cells
B7-1 Inducible: APCs (slower  kinetics 
than B7-2), T cells
CTLA-4 (CD152)
Inducible: T cells; 
constitutive: Tregs
Inhibition of TCR-dependent activation: ↓ proliferation (↑ 
p27Kip1, ↓ G1/S); ↓ cytokine production (↓ NFκB, ↓ IL2); CD28-
dependent and -independent functions; promotes inhibitory 
function of Tregs.
Blockade of pathway in tumor 
 immunotherapy; receptor poly-
morphisms linked with autoimmunity
B7-2 Constitutive at low levels; 
inducible: APCs, T cells
Icosl 
(B7h, B7-H2, 
CD275, LICOS, 
B7RP-1)
Induced by TNFα and IFNγ: 
APCs, T cells, fi broblasts, 
endothelium
ICOS (CD278)
Inducible: T cells (CD28-
dependent and CD28-
 independent); constitutive: 
resting memory T cells, Tregs
Stimulation: ↑ proliferation (modest compared to CD28); ↑ 
cytokine production by effector T cells (IL4 > IFNγ); ↑ survival 
(↑ Bcl-xL, ↑ IL23-mediated survival of Th17); ↑ GC forma-
tion and isotype class switching. Inhibition: ↑ IL10 cytokine 
production.
Receptor polymorphisms  associated 
with immunodefi ciency and 
 autoimmunity
Pd-l1 
(B7-H1, CD274)
Constitutive (mouse), induced 
by IFNα/β/γ: APCs, T cells, 
nonhematopoieitic cells; 
 overexpressed in tumor cells
PD-1 (CD279)
Inducible: T cells, double-
negative thymocytes, B cells, 
myeloid cells; 
constitutive: exhausted T cells 
during chronic viral infection
Inhibition: ↓ TCR signals through recruitment of protein tyrosine 
phosphatases (most effective at low levels of TCR signaling); ↓ 
cytokine production (↓ IL2, IFNγ, TNFα); ↓ proliferation (↓ G1/S); 
↓ cytokine production greater than ↓ proliferation; ↓ survival (↓ 
Bcl-xL); ↓ CTL-mediated lysis.
Active engagement induces tolerance; 
↑ PD-L1 on human tumors associated 
with poor prognosis (potential for 
blockade as therapy); ↑ PD-1 on T 
cells associated with poorer function 
in chronic viral infection (potential for 
blockade as therapy)
Pd-l2 (B7-DC, 
CD273)
Inducible: DCs,  macrophages, 
placenta (human); over-
expressed in tumor cells
B7-1 see above PD-L1 (B7-H1; CD274) Inhibition of T cell proliferation see above
Pd-l1 see above B7-1 (CD80) Inhibition of T cell proliferation see above
B7-H3 (CD276) Inducible: T cells, B cells, DCs, 
NK cells; overexpressed in 
tumor cells
TLT-2 (TREM receptor family; 
mouse only)
Constitutive: CD8+ T cells, 
B cells, macrophages, DCs; 
inducible: CD4+ T cells
Stimulation of CD8+ T cells: ↑ proliferation; ↑ cytokine 
 production (↑ IFNγ and IL2); blockade leads to ↓ contact 
hypersensitivity in vivo.
Costimulatory effect of B7-H3 may 
regulate antitumor cytotoxic T cell 
 immune responses
B7-H4 
(B7S1, B7x)
Inducible: T cells, B cells, DCs, 
monocytes; overexpressed in 
tumor cells
Receptor not yet identifi ed
Putatively inducible on T cells
Inhibition of T cell proliferation: ↓ cytokine production (↓ IL2 
and IL4); blockade/knockdown leads to ↑ EAE and tumor cell 
apoptosis.
Potential role in tumor immunotherapy
Btnl2 
(BTL-II)
Inducible: T cells, B cells Receptor not yet identifi ed
Putatively inducible on T cells
Inhibition of CD4+ T cell function in vitro: ↓ proliferation of CD4+ 
T cells; ↓ ICOSL-mediated cytokine production (↓ TNFα, IFNγ, 
IL2, IL4, IL6, IL10, and IL17); ↓ activity of AP1, NFAT, and NFκB.
Polymorphisms/mutations in BTNL2 
gene associated with sarcoidosis and 
inclusion body myositis
HVem 
(TNFR super-
family member)
Constitutive, ↓ upon activation: 
naive T cells, naive B cells, im-
mature DCs, memory T and B 
cells, nonhematopoietic cells
BTLA (CD272)
Inducible: T cells (↑ on anergic 
T cells), DCs; constitutive: 
B cells
CD160, LIGHT
Inhibition of CD4+ T cell proliferation: ↓ cytokine production (↓ 
IL2); defi ciency promotes EAE and allograft rejection in vivo; 
BTLA-defi cient mice develop autoimmune-like disease.
Pathway blockade enhances immune 
responses; one polymorphism associ-
ated with ↑ risk of rheumatoid arthritis
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Table: Binding Partners in the B7/CD28 Family of Costimulatory Molecules
T cells require two signals for optimal activation. The first signal is delivered to the T cell receptor (TCR) by processed antigen displayed by major histocompatibility 
complex (MHC) molecules; this antigen-dependent signal provides specificity to the immune response. The second signal, known as the costimulatory signal, is deliv-
ered to receptors on T cells by costimulatory molecules. These cell-surface molecules provide contextual information that influences the ensuing immune response. 
Costimulatory signals can have either stimulatory or inhibitory effects on T cells. As several interactions can occur throughout the activation and effector phases of the 
immune response, it appears that the overall balance between positive and negative costimulation directs the magnitude, location and type of response. Temporal and 
spatial regulation of expression of both costimulatory receptors and ligands leads to dynamic modulation of T cell priming, homing, and effector function. Importantly, 
these molecules potentially can be targeted for therapy to block undesirable immune activation, for example during autoimmune disease or organ transplant rejection, 
or to stimulate desired immune responses to combat cancer or infection. The best described costimulatory interactions are those in the B7/CD28 family. B7 family 
members typically act as ligands for CD28 receptor family members, although B7-1 and PD-L1 (both B7 family members) can also act as receptors themselves. There 
are also crossfamily interactions, such as B7-H3 binding to the TREM receptor family member TREM-like transcript-2 (TLT-2) and BTLA binding to HVEM . HVEM also 
binds to LIGHT (TNF superfamily, member 14) and to lymphotoxin α to stimulate T cell responses; HVEM can also bind to CD160, an Ig superfamily member, to inhibit 
T cell responses. Other members of the B7/CD28 family may still await discovery, and alternative receptors for known family members may exist. For example, there 
are data to suggest the existence of a stimulatory receptor for PD-L1 and PD-L2. B7-H3 may also interact with a putative inhibitory receptor on T cells in addition to the 
stimulatory TLT-2.
Figure: B7/CD28 Family Interactions and Signaling Pathways
B7/CD28 family members are defined structurally by their common IgC-IgV extracellular binding domains, and signaling pathways are driven primarily by intracellular 
tyrosine-containing motifs. Apart from the specific antigen-dependent signal provided by the MHC-antigen complex to the TCR, the cell-surface interactions involving 
the B7/CD28 family of costimulatory molecules provide a second signal to T cells to enhance or inhibit the canonical TCR signaling pathway, leading to changes in T cell 
proliferation, survival, and cytokine production. Human B7-H3 has an extracellular domain composed of IgV-IgC-IgV-IgC, whereas the mouse form of B7-H3 (shown in 
the figure) consists of an IgV-IgC extracellular domain.
Abbreviations
AP1, activator protein 1; APCs, antigen-presenting cells; B7-H, B7 homolog; BTLA, B and T lymphocyte attenuator; BTNL2, butyrophilin-like 2; CTL, cytotoxic T lympho-
cyte; CTLA-4, cytotoxic T lymphocyte antigen-4; DCs, dendritic cells; EAE, experimental autoimmune encephalomyelitis; GC, germinal center; GVHD, graft-versus-host 
disease; HVEM, herpesvirus entry mediator; ICOS, inducible costimulator; ICOSL, ICOS ligand; IFN, interferon; Ig, immunoglobulin; IL, interleukin; LIGHT, homologous 
to lymphotoxins, exhibits inducible expression, and competes with herpes simplex virus glycoprotein D for HVEM, a receptor expressed by T lymphocytes; mTOR, mam-
malian target of rapamycin; NFAT, nuclear factor of activated T cells; NFκB, nuclear factor kappa B; NK, natural killer; PD-1, programmed death-1; PD-L, programmed 
death-1 ligand; PI3K, phosphatidylinositol 3 kinase; PLC, phospholipase C; Th17, IL17-producing helper T cell; TNF, tumor necrosis factor; TNFR, TNF receptor; Tregs, 
regulatory T cells; TREM, triggering receptor expressed on myeloid cells; ZAP70, zeta-associated protein kinase 70.
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